Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of MK-0616 in Adults With Hypercholesterolemia
jRCT2051240110Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2024
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of enlicitide in hypercholesterolemia, sponsored by Merck & Co. Primary endpoints: Number of participants with one or more adverse events and Number of participants who discontinue study drug due to an adverse event. Started Oct 2024; status: active, not recruiting.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on jRCT2051240110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240110.